Follow us
History of NHT
Filters : all - All
- Award
- Clinical Development
- Governance and Finances
- Manufacturing of AGuIX®
- Publication grants and patents
NH TherAguix Appoints Jean-Philippe DEL as Chief Finance Officer2023 NH TherAguix appoints Vincent Carrère as CEO – Géraldine Le Duc (co-founder) becomes COO/CSO and member of the Board.2023 December – Ph.D defence of Désirée Tannous (CIFRE IGR-NHT) and of Clara Diaz (collaboration Montpellier University)2022 October – Thesis defense of Dr. Paul Rocchi as the first NHT-funded PhD student2022 September – Recruitment of Olivier de Beaumont as Chief Medical Officer.2022 March – First patient enrolled in clinical trial Nano-GBM targeting glioblastoma with institut Jean PERRIN in Clermont-Ferrand, France.2022 January – Obtainment of the ODD from the EMA for the treatment of pancreatic cancer with AGuIX®2022 December – Obtainment of the ODD from the EMA for the treatment of glioblastoma with AGuIX®2021 October – First patients enrolled in NanoBrainMets and NanoSmart clinical trials at Dana-Farber Brigham Cancer Center, Boston (USA)2021 October – Prize Ernst & Young: “Entrepreneur de l’année, prix spécial du jury”.2021 Production of the fourth batch of human injectable drug manufactured by SANOFI/CARBOGEN AMCIS2021 May – Obtainment of the ODD from the US FDA for the treatment of glioblastoma with AGuIX®2021 April – Second publication about the First-In-Human trial NANORAD in Radiotherapy & Oncology2021 View Article
February – Obtainment of the ODD from the US FDA for the treatment of pancreatic cancer with AGuIX®2021 Internalization of MRI Data analysis knowledge and know how (arrival of Fabien Boux as MRI Engineer and support from Yannick Crémillieux as MRI expert)2021 Arrival of Michel Julien as Head of Chemistry Manufacturing and Control2020 Leverage of €6M of non dilutive funds performed including bank loans, BPI subsidies and academic grant (NIH, ANR)2020 Second patent with Harvard Medical School (MRI-Linac) and Grant NIH $3M related to the collaboration with Harvard Medical School2020 October – Investigational New Drug (IND) becomes active2020 Publication on the radiosensitization mechanism of AGuIX®2020 View Article
First publication about the First-In-Human trial NANORAD in Science Advances2020 View Article
Production of the third batch of human injectable drug manufactured by SANOFI/CARBOGEN AMCIS2020 Structuration of the Clinical Development unit – Recruitment of Markus Loeffler as Chief Medical Officer and Khalide Seddik as Clinical Operations Responsible2020 Final report of NANORAD Phase 1 clinical trial and start of NANORAD 2 multicentric Phase 2 clinical trial2019 Creation of Administrative & Financial unit (arrival of Caroline Cayre and Florence Cruz)2019 Appointment of Hervé Brailly as Chairman of the Supervisory Board2019 Series A funding (13M€) – BPI Innobio2, Arbevel, Omnes, Supernova2019 Prize Galien (MedStartUp) (New York) – Third prize for the “Best collaboration in the pharmaceutical or biotechnology industry in 2019” related to the collaboration with Dana Farber Cancer Institute2019 Prize IMPI awarded to ILM – Fennec Team (Olivier Tillement)2018 Review article on AGuIX® by François Lux et al. in The British Journal of Radiology2018 View Article
Production of the second batch of human injectable drug manufactured by CARBOGEN AMCIS2018 Prize “Business with Attitude” awarded to Géraldine Le Duc CEO (Entreprenariat féminin, Figaro Madame)2018 Start of NANOCOL Phase 1 clinical trial on cervical cancer at Institut Gustave Roussy2017 Research collaboration with Institut Gustave Roussy2017 Creation of Chemistry Manufacturing and Control unit (arrival of Tristan Doussineau) and beginning of partnership with SANOFI for API manufacturing2017 First Patent with Harvard Medical School2017 First-in-human injection of AGuIX® in the frame of NANORAD Phase 1 clinical trial on brain metastases at CHU Grenoble Alpes2016 Prize R2B Onco Cancéropole Lyon2016 Prizes « Tremplin Entreprises » Sénat -ESSEC & « Coup de Cœur » France Biotech2016 Research collaboration with Institut Lumière Matière2015 2015/2016 Inception of NHT by four co-founders Géraldine Le Duc, Olivier Tillement, François Lux, Sandrine Dufort2015 Production of the first batch of human injectable drug manufactured by CARBOGEN AMCIS2015 Princeps patent on AGuIX®2011 Design of a new optimized structure: the ultrasmall AGuIX nanoparticle2010 2005-2010: First demonstration of the radiosensitizing effect of gadolinium-based nanoconstructs2005 First radiosensitization studies on molecular and nanoparticular compounds containing high-Z elements2005
Manage Cookie Consent We use cookies to optimize our website and our service.
Fonctionneal Fonctionneal Always active The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Preferences Preferences The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. Statistiques Statistiques The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage options Manage services Manage {vendor_count} vendors Read more about these purposes Accept Deny Preferences Save preferences Preferences {title} {title} {title} Gérer le consentement